| A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor (NCT05148442) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-12-28 |
| Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 (NCT05199519) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-12-13 |
| Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer (NCT05088967) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-12-02 |
| Evaluation of IBI302 Injection in nAMD or DME (NCT05961007) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-11-18 |
| IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC) (NCT05118334) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-11-12 |
| A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (NCT05043298) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-10-27 |
| Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) (NCT05039658) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-27 |
| A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis (NCT05003531) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-23 |
| A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations (NCT05005234) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-13 |
| A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (NCT05026593) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-07 |
| A Study of IBI362 in Chinese Patients With Type 2 Diabetes (NCT04965506) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-06 |
| Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects (NCT05005455) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-07-30 |
| IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors. (NCT04912466) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-07-21 |
| Study of IBI323 in Patients With Advanced Malignancies (NCT04916119) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-29 |
| A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors (NCT04911881) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-24 |
| A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors (NCT04911894) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-21 |
| A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (NCT04904913) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-08 |
| A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC (NCT04672369) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-06-06 |
| A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers (NCT04868760) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-05-31 |
| IBI188 Combination Therapy in Solid Tumors (NCT04861948) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-05-25 |
| A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy (NCT04795128) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-05-07 |
| A Study of IBI302 in Patients With nAMD (NCT04820452) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-04-28 |
| Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors (NCT04708210) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-04-28 |
| A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) (NCT04675983) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-03-10 |
| Clinical Study of IBI362 in Healthy Chinese Male Subjects (NCT04773977) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-03-03 |
| A Study of IBI306 in Participants With Hypercholesterolemia (NCT04709536) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-02-09 |
| A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC (NCT04720716) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-02-07 |
| A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer (NCT04672356) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-01-25 |
| A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers (NCT04338659) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-01-14 |
| A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma (NCT04635527) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-12-24 |
| A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies (NCT04672928) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-12-14 |
| A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy (NCT04590599) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-12-08 |
| Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial (NCT04602065) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-11-24 |
| Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS (NCT04485065) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-30 |
| Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (NCT04485052) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-25 |
| Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM (NCT04466904) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-12 |
| IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer (NCT04258111) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-08-27 |
| Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects (NCT04511624) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-08-27 |
| A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS (NCT04511975) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-08-24 |
| Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors (NCT04328831) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-07-31 |
| A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor (NCT04427774) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-29 |
| A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease (NCT04220632) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-18 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects (NCT04440345) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-16 |
| Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma (NCT04401813) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-16 |
| Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients (NCT04370379) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-05-28 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors (NCT04353830) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-05-22 |
| Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia (NCT04289285) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-04-29 |
| The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery (NCT04277663) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-04-17 |
| IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma (NCT04298879) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-04-07 |
| Intense Monitoring Study on Tyvyt (NCT04237233) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-04-02 |
| A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients (NCT04177290) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-04-02 |
| Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations (NCT04258527) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-03-26 |
| Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement (NCT04256980) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-03-03 |
| Safety and Efficacy of IBI306 in HeFH Patients (NCT04179669) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-12-20 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors (NCT04085185) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-12-04 |
| A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor (NCT04162327) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-11-26 |
| A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy (NCT04044222) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-10-21 |
| A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia (NCT04031742) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-09-29 |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure (NCT03802240) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-07-11 |
| A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration (NCT03814291) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-04-15 |
| A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas (NCT03763149) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-19 |
| First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors (NCT03758001) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-13 |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. (NCT03794440) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-02-11 |
| A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies (NCT03717103) | Innovent Biologics (Suzhou) Co. Ltd. | 2019-01-10 |
| Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (NCT03748134) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-12-24 |
| Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC (NCT03629925) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-09-28 |
| A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. (NCT03545971) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-09-25 |
| Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC (NCT03607539) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-08-23 |
| IBI308 in Subjects With Advanced/Metastatic Solid Malignancies (NCT03568539) | Innovent Biologics (Suzhou) Co. Ltd. | 2018-06-27 |
| Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects. (NCT03366688) | Innovent Biologics (Suzhou) Co. Ltd. | 2017-11-27 |
| A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC (NCT03150875) | Innovent Biologics (Suzhou) Co. Ltd. | 2017-09-01 |